Searchable abstracts of presentations at key conferences in endocrinology

ea0009p32 | Diabetes and metabolism | BES2005

Rosiglitazone and phenformin, but not metformin activate AMP-activated protein kinase and stimulate nitric oxide release in human aortic endothelial cells

Boyle J , Cleland S , Salt I , Connell J

Thiazolidinediones and biguanides improve insulin resistance and are used in the management of type 2 diabetes. Use of biguanides is associated with a reduction in vascular complications in patients with diabetes. Pre-clinical studies with thiazolidinediones suggest improvements in vascular function and long-term clinical trials in type 2 diabetes are in progress. These effects are proposed to be mediated through inhibition of complex 1 in the mitochondrial respiratory chain a...

ea0004oc31 | Neuroendocrinology and diabetes | SFE2002

EFFECT OF COMBINED HORMONE REPLACEMENT THERAPY ON GLUCOSE METABOLISM IN POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES; A RANDOMISED CONTROLLED TRIAL

Kernohan A , Lumsden M , Cleland S , Petrie J , Connell J

Prescription rates for HRT in women with type 2 diabetes are low. One reason for this is concern about adverse metabolic effects although evidence on this is limited. We report results from a 3-month randomised, double blind, placebo-controlled trial of 1mg 17-beta oestradiol combined with 0.5 mg norethisterone acetate in postmenopausal women with type 2 diabetes. The study has full local ethics committee approval.29 subjects entered the study; 1 taking ...

ea0004dp23 | Diabetes, metabolism and cardiovascular | SFE2002

EFFECT OF COMBINED HORMONE REPLACEMENT THERAPY ON GLUCOSE METABOLISM IN POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES; A RANDOMISED CONTROLLED TRIAL

Kernohan A , Lumsden M , Cleland S , Petrie J , Connell J

Prescription rates for HRT in women with type 2 diabetes are low. One reason for this is concern about adverse metabolic effects although evidence on this is limited. We report results from a 3-month randomised, double blind, placebo-controlled trial of 1mg 17-beta oestradiol combined with 0.5 mg norethisterone acetate in postmenopausal women with type 2 diabetes. The study has full local ethics committee approval.29 subjects entered the study; 1 taking ...